ENOB - Enochian Bio reports preliminary data from HIV cell therapy in humans

Enochian BioSciences ([[ENOB]] +7.3%) announces the release of preliminary data relating to the use of a novel cell therapy approach in controlling HIV in humans.The findings were presented at the Annual Meeting of the American Society of Gene and Cell Therapy ((ASGCT)).A 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.With approval from an Institutional Review Board, this single patient was treated with a novel cellular therapy of natural killer ((NK)) and gamma delta T-cells ((GDT)).The NK and GDT cells were collected from a person who does not have HIV. Because the patient stopped antiviral treatment and received some supportive medication before the cellular therapy, the level of HIV initially increased, as expected. However, HIV levels began to decline after approx. three weeks, and after 100 days dropped below the detection level of routinely used blood tests (20 copies/ml).HIV levels in the

For further details see:

Enochian Bio reports preliminary data from HIV cell therapy in humans